- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07944235
Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery (PREOPRAD)
Randomized Phase II/III Study Comparing Preoperative Radiosurgery Versus Postoperative Radiosurgery in Patients With Brain Metastases Eligible for Surgery: Correlation With Histopathological Factors and Radiomic Analysis.
The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.
More specifically, the study seeks to:
- Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
- Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
- Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.
PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.
The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Badajoz
-
Badajoz, Badajoz, Espanja, 06080
- Ei vielä rekrytointia
- Hospital Universitario de Badajoz
-
Ottaa yhteyttä:
- Victoria Vera Barragán, MD
- Puhelinnumero: +34924 21 81 00
- Sähköposti: victoria.vera@salud-juntaex.es
-
-
Galicia
-
Vigo, Galicia, Espanja, 36214
- Ei vielä rekrytointia
- Hospital do Meixoeiro
-
Ottaa yhteyttä:
- Beatriz Vazquez Barreiro, MD
- Puhelinnumero: +34 986 81 11 11
- Sähköposti: Beatriz.vazquez.barreiro@sergas.es
-
-
Madrid
-
Madrid, Madrid, Espanja, 28034
- Rekrytointi
- Hospital Universitario Ramón y Cajal
-
Ottaa yhteyttä:
- Eva Lizarbe Fernández, MD
- Puhelinnumero: +3491 336 82 22
- Sähköposti: eva.lizarbe@gmail.com
-
Madrid, Madrid, Espanja, 28034
- Ei vielä rekrytointia
- Hospital Ruber Internacional
-
Ottaa yhteyttä:
- Rafael Garcia Garcia, MD
- Puhelinnumero: +34913 87 50 00
- Sähköposti: rafael.garciag.ce@ruberinternacional.es
-
-
Navarre
-
Pamplona, Navarre, Espanja, 31008
- Rekrytointi
- Hospital Universitario de Navarra
-
Ottaa yhteyttä:
- Paola Anna Jablonska, MD
- Puhelinnumero: +34848 428 482
- Sähköposti: paolajablonska@gmail.com
-
Ottaa yhteyttä:
- Cristina Gutierrez, PhD
- Puhelinnumero: +34848433454
- Sähköposti: cristina.gutierrez.povedano@navarra.es
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed solid tumor with one to four brain metastases.
- At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
- Karnofsky Performance Status (KPS) ≥70.
- Life expectancy ≥3 months.
- Ability to undergo MRI examinations.
- Written informed consent provided.
Exclusion Criteria:
- Brain metastases from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
- Prior radiotherapy to the index lesion.
- Leptomeningeal disease at baseline.
- Contraindication to surgery or stereotactic radiosurgery.
- Pregnancy or breastfeeding.
- Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: preoperative radiosurgery
preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Muut nimet:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
|
Muut: postoperative radiosurgery
standard treatment, consisting of surgical resection followed by irradiation of the tumor bed |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Muut nimet:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Locoregional adverse event-free survival
Aikaikkuna: From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed. |
From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Meningeal Failure Rate
Aikaikkuna: 6 and 12 months after randomization.
|
Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI). |
6 and 12 months after randomization.
|
|
Symptomatic Radiation Necrosis Rate
Aikaikkuna: 6 and 12 months after randomization.
|
Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation. |
6 and 12 months after randomization.
|
|
Local Control Rate
Aikaikkuna: 6 and 12 months after randomization.
|
Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI. |
6 and 12 months after randomization.
|
|
Distant Brain Failure-Free Survival
Aikaikkuna: 6 and 12 months after randomization.
|
Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s). |
6 and 12 months after randomization.
|
|
Overall Survival
Aikaikkuna: 6 and 12 months after randomization.
|
Time from randomization to death from any cause. |
6 and 12 months after randomization.
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to Whole-Brain Radiotherapy (WBRT)
Aikaikkuna: From randomization until administration of WBRT, up to 42 months.
|
Time from randomization to the administration of whole-brain radiotherapy (WBRT). |
From randomization until administration of WBRT, up to 42 months.
|
|
Health-Related Quality of Life
Aikaikkuna: Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden). |
Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
|
Length of Hospital Stay
Aikaikkuna: From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge. |
From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
|
Treatment Delay
Aikaikkuna: From treatment planning to treatment completion, up to 42 months.
|
Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment. |
From treatment planning to treatment completion, up to 42 months.
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Aivojen sairaudet
- Keskushermoston sairaudet
- Hermoston sairaudet
- Patologiset prosessit
- Neoplasmat sivustoittain
- Neoplasmat
- Neoplastiset prosessit
- Hermoston kasvaimet
- Keskushermoston kasvaimet
- Patologiset tilat, merkit ja oireet
- Neoplasman metastaasit
- Aivojen kasvaimet
- Tutkintatekniikat
- Terapeuttiset lääkkeet
- Kirurgiset toimenpiteet, operatiivinen
- Sädehoito
- Stereotaksiset tekniikat
- Neurokirurgiset toimenpiteet
- Radiokirurgia
Muut tutkimustunnusnumerot
- PREOPRAD
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .